Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "9169", "attributes": { "award_id": "75N92020C00015-P00001-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-28", "end_date": "2021-08-27", "award_amount": 24369230, "principal_investigator": { "id": 24932, "first_name": "STUART HELLYAR HELLYAR", "last_name": "HELLYAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A battery powered, POC/at home device for the quantitation and detection of SARS-CoV-2 simultaneously with Influenza A & B, with the accuracy, specificity and sensitivity equivalent to or better than the current CDC RT-PCR Lab based methodology.", "keywords": [ "COVID-19 detection", "Centers for Disease Control and Prevention (U.S.)", "Devices", "Home", "Influenza A virus", "Influenza B Virus", "Methodology", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Sensitivity and Specificity", "base", "programs" ], "approved": true } }, { "type": "Grant", "id": "8432", "attributes": { "award_id": "75N92021C00018-0-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 3700000, "principal_investigator": { "id": 22342, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "9197", "attributes": { "award_id": "75N92020C00017-P00001-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT NO 2375 - MASSIVELY PARALLEL CENTRALIZED AND DECENTRALIZED ULTRAFAST COVID-19INFECTIOUS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 7200049, "principal_investigator": { "id": 24949, "first_name": "DAVID", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "Conscious", "Decentralization", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "coronavirus disease", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "programs", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "4102", "attributes": { "award_id": "NNX16AK48G", "title": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2016-05-23", "end_date": "2017-05-22", "award_amount": 0, "principal_investigator": { "id": 13774, "first_name": "CYRENA", "last_name": "GOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9280", "attributes": { "award_id": "75N91020C00035-0-9999-1", "title": "DIGITAL HEALTH SOLUTIONS FOR COVID-19: CLEAR2GO", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-14", "end_date": "2020-11-27", "award_amount": 274880, "principal_investigator": { "id": 25020, "first_name": "ADARBAD", "last_name": "MASTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1816, "ror": "", "name": "ICRYPTO, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "The goal of this project is to develop a smartphone-based platform to provide irrefutable proof of testing, serologic, and vaccination status for individuals. The customized solution, called Clear2Go (C2G), maps a person’s vetted identity and biometrics to their phone and then cryptographically binds it with their COVID-19 test results or other personal health information. C2G is intended to provide individuals, employers, government agencies, and other organizations with a convenient solution to evaluate the risks associated with an individual’s return to normal work, travel, and public life activities. The aims of this project include creating the C2G solution, demonstrating that C2G can be integrated with the publicly available interface of a test laboratory portal, and conveying simulated COVID-19 test results into the C2G application. Data collected under this project will be deidentified and securely transmitted to an NIH data hub.", "keywords": [ "Binding", "Biometry", "COVID-19", "Cellular Phone", "Custom", "Data", "Goals", "Government Agencies", "Health", "Individual", "Laboratories", "Life", "Maps", "Persons", "Risk", "Secure", "Serological", "Telephone", "Test Result", "Testing", "Travel", "United States National Institutes of Health", "Vaccination", "Work", "base", "cryptography", "data hub", "digital" ], "approved": true } }, { "type": "Grant", "id": "4728", "attributes": { "award_id": "NNX13AG97G", "title": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2013-02-11", "end_date": "2017-02-10", "award_amount": 0, "principal_investigator": { "id": 16385, "first_name": "ERIC", "last_name": "WOOD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "8097", "attributes": { "award_id": "75N92021C00003-P00002-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2023-01-31", "award_amount": 2500000, "principal_investigator": { "id": 23980, "first_name": "TODD", "last_name": "WOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Resubmission of Application 3136. This product concept has been updated to include Flu viral targets along with SARS-CoV-2. The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020. The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.", "keywords": [ "2019-nCoV", "Acute", "Biological Assay", "COVID-19 assay", "COVID-19 patient", "Clinical", "Communicable Diseases", "Computer software", "Coupled", "Detection", "Molecular", "Patients", "RADx Tech", "RNA Sequences", "Reporting", "Running", "Seasons", "Specimen", "Technology", "Time", "Update", "Viral", "Virus", "Virus Diseases", "base", "betacoronavirus", "flu", "instrument", "respiratory", "waiver" ], "approved": true } }, { "type": "Grant", "id": "6681", "attributes": { "award_id": "75N92021C00018-P00002-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 12970000, "principal_investigator": { "id": 22379, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Persons", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "9536", "attributes": { "award_id": "2030139", "title": "Compounding Crises: Facing Hurricane Season in the Era of COVID-19", "funder": null, "funder_divisions": [], "program_reference_codes": [ "CK090", "RND123" ], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 199890, "principal_investigator": null, "other_investigators": [], "awardee_organization": null, "abstract": "Test", "keywords": [ "covid", "research" ], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1424, "count": 14236 } } }